Trial Profile
A Randomized, Double-blind, Parallel Group, Multicenter, Stratified Study Evaluating the Efficacy and Safety of Repeat Doses of GSK3772847 Compared With Placebo in Participants With Moderately Severe Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Aug 2023
Price :
$35
*
At a glance
- Drugs Melrilimab (Primary) ; Fluticasone propionate; Salmeterol/fluticasone propionate
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 17 Jun 2019 Status changed from active, no longer recruiting to completed.
- 13 Dec 2018 Planned End Date changed from 9 May 2019 to 23 May 2019.
- 13 Dec 2018 Planned primary completion date changed from 14 Feb 2019 to 28 Feb 2019.